The efficacy and safety of exogenous melatonin in the treatment of acute central serous chorioretinopathy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300073143

Enrollment

Unknown

Registered

2023-07-03

Start date

2023-07-10

Completion date

Unknown

Last updated

2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Serous Chorioretinopathy

Interventions

Placebo controll group:Placebo 1 capsule/day for 3 months

Melatonin intervention group:Melatonin 10mg/day for 3 months

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 18-60 years old; The course of the disease don't exceed 3 months; Ametropia within ±6D; FFA shows focal leakage points.

Exclusion criteria

Exclusion criteria: The best corrected visual acuity of the fellow eye is3 months); Recurrent patients; Inability to complete fundus examination due to unclear refractive medium; Sodium fluorescein allergy; Severe liver and kidney diseases; FFA shows diffuse leakage or related examination shows neovascularization; Pregnant or lactating women; Eye related diseases such as cataracts, keratitis, glaucoma, uveitis, and hereditary eye diseases; Previous history of eye disease treatment, such as PPV, laser, anti VEGF, PDT treatment, etc

Design outcomes

Primary

Measure	Time frame
Subretinal fluid height ;	—

Secondary

Measure	Time frame
contrast sensitivity;choroidal vascularity index;best corrected visual acuity;Choroid thickness;PSQI Questionnaire Score;NEI-VFQ-25 Questionnaire Score;Urine 6-hydroxysulfate Melatonin (UME) level;	—

Countries

China

Contacts

Public ContactLiang Xiaoling

Zhongshan Ophthalmic Center, Sun Yat-sen University

liangxiaoling@gzzoc.com+86 173 0666 7271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026